China Reforms Welcome, But More Needed – Frazier
This article was originally published in The Pink Sheet Daily
Executive Summary
Visiting Beijing, PhRMA chairman Kenneth Frazier noted the need for drug companies to adopt flexible pricing practices in the Chinese market, and urges China to adopt regular reimbursement review after regulatory approval and more timely updates to government drug lists.
You may also be interested in...
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms
The strategy of publicly criticizing pharmaceutical companies, albeit non-members, is an unusual one for PhRMA. But it demonstrates the group’s interest in playing offense, and not just defense, in the drug price debate.
Hengrui, Affiliate Reistone In Apparent Dispute Over China Ivarmacitinib NDAs
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.